Advancing a targeted therapy for Leber’s Hereditary Optic Neuropathy, an inherited form of vision loss
Fortify Therapeutics is dedicated to developing a safe and effective treatment for patients with Leber’s Hereditary Optic Neuropathy, or LHON, a rare mitochondrial genetic disorder that leads to loss of central vision predominantly in young adults.
LHON is driven by mutations in subunits of the NADH dehydrogenase complex. These mutations reduce the ability of the retinal cells to produce energy, resulting in their degeneration. Fortify Therapeutics is currently developing a localized therapy to bypass the dysfunctional metabolic pathway in this disease and provide an alternate source of energy to the retinal cells of LHON patients.